Update: ETS2101 progressing into Phase Ib trial
The UK Phase Ia study of ETS2101 in solid tumours has established the maximum tolerated dose (MTD) and reported no serious drug-related events other than somnolence. This clears the path for the start of the Phase Ib element in Q115 for the two initial indications of hepatocellular and pancreatic cancers. e-Therapeutics’ solid cash position means it can support development of the clinical programmes to key value inflection points as well as the investment in optimising its discovery activities.E-Therapeutics is a drug discovery company with a proprietary in silico discovery platform based on the application of network science to the modelling and analysis of cellular processes and utilizing public and proprietary chemical biology and multi-omics data. The therapeutic focus of Co.'s discovery activity is in areas of disease with unmet medical need, including immuno-oncology.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.